Recurrent genetic alterations in hepatitis C-associated hepatocellular carcinoma detected by genomic microarray: a genetic, clinical and pathological correlation study

Molecular Cytogenetics

Matthew M Yeh¹  Yang Zhou¹  Yajuan J Liu¹ 

[1] Department of Pathology, University of Washington, 1959 NE Pacific Street, Seattle 98195, WA, USA

关键词: Pathological correlation;    Prognosis;    Genomic microarray;    Copy number variants;    Copy number aberration;    Hepatitis-C virus;    Hepatocellular carcinoma;   

Others  :  1162996
DOI  :  10.1186/s13039-014-0081-8

 received in 2014-07-16, accepted in 2014-10-26,  发布年份 2014

【 摘 要 】

Background

In the US, approximately 50% of hepatocellular carcinoma (HCC) is caused by hepatitis-C virus (HCV) infection. The molecular mechanism of a malignant transformation of hepatocyte induced by HCV infection is still largely unclear. There are several clinical and pathological staging systems for HCC, but none of them include biological parameters as predictors for prognosis and there has not been a standardized molecular classification of HCC. To understand the underlying pathogenic genetic alterations in HCV-associated HCC and aid in molecular classification of HCC and patient prognosis, microarray analysis of DNA copy number alterations in HCC were conducted using whole genome microarray with DNA from formalin-fixed paraffin-embedded (FFPE) specimens of both cancer tissues and paired nearby cirrhotic non-neoplastic tissues.

Results

Our results show that the most common chromosomal aberrations (>5 Mb) observed in HCC were chromosomal gains of 1q (80%), 8q (60%), 7q (40%), 5p (33%), 7p (33%), Xq (33%), 5q (27%), and Xp (20%), as well as chromosome losses of 17p (40%), 4q21.21-q26 (33%), 8p (33%), 1p36.11-pter (20%), and 9p (20%). Statistically significant smaller copy number alterations (3.9 kb to 644 kb) were identified using STAC algorithm, including losses of FGFR3, RECQL4, NOTCH1, PTEN, TSC2, and/or ASPSCR1 and gains of ETV1and/or MAF. Correlation analysis between genetic data and pathological data showed that gain of 1q21.1-q23.2 and gain of 8q11.1q13.1 are significantly associated with grade 2¿4 and moderately or poorly differentiated HCCs, and gain of chromosome 5q was significantly associated with HCCs with vascular invasion, while gain of chromosome 7q is significantly associated with stage I HCCs.

Conclusions

This study has provided a detailed map of genomic aberrations occurring in HCV-associated HCC and has suggested candidate genes. In addition, gene enrichment analysis on the recurrent abnormal regions indicated NF- kappaB and BMP signaling pathways in HCC development and progression. This study demonstrated that genomic microarray test can be used to distinguish HCC from non- neoplastic cirrhotic nodules and to identify prognostic factors associated with HCC progression using pathologically characterized FFPE samples. Our data support the utility of genomic microarray test for the diagnosis, risk stratification, and pathogenic studies of HCC.

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Munoz N, Bosch X: Epidemiology of Hepatocellular Carcinoma. In Neoplasms of the Liver. Edited by Okuda K, Ishak KG. Springer, Tokyo; 1989:3.
• [2]Bosch F, Munoz N: Hepatocellular Carcinoma in the World: Epidemiologic Questions. In Etiology, Pathology and Treatment of Hepatocellular Carcinoma in America, Advances in Applied Technology Series. Edited by Tabor E, DiBisceglie AM, Purcell RH. Gulf, Houston; 1991:35.
• [3]Hashem BE-S: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
• [4]Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
• [5]Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F, Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F: Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000, 32:200-204.
• [6]Niederau C, Lange S, Heintges T: Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998, 28:1687-1695.
• [7]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
• [8]Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:055,076.
• [9]Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S, Oga A, Furuya T, Tangoku A, Oka M, Sasaki K: Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 2004, 17:617-622.
• [10]Sakakura C, Hagiwara A, Taniguchi H, Yamaguchi T, Yamagishi H, Takahashi T, Koyama K, Nakamura Y, Abe T, Inazawa J: Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer 1999, 80:2034-2039.
• [11]Guo X, Yanna , Ma X, An J, Shang Y, Huang Q, Yang H, Chen Z, Xing J: A meta-analysis of array-CGH studies implicates antiviral immunity pathways in the development of hepatocellular carcinoma. PLoS One 2011, 6:e28404.
• [12]Zondervan PE, Wink J, Alers JC JNIJ, Schalm SW, de Man RA, van Dekken H: Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol 2000, 192:207-215.
• [13]Homayounfar K, Schwarz A, Enders C, Cameron S, Baumhoer D, Ramadori G, Lorf T, Gunawan B, Sander B: Etiologic influence on chromosomal aberrations in European hepatocellular carcinoma identified by CGH. Pathol Res Pract 2013, 209:380-387.
• [14]Tornillo L, Carafa V, Richter J, Sauter G, Moch H, Minola E, Gambacorta M, Bianchi L, Vecchione R, Terracciano LM: Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. J Pathol 2000, 192:307-312.
• [15]Strachan GD, Jordan-Sciutto KL, Rallapalli R, Tuan RS, Hall DJ: The E2F-1 transcription factor is negatively regulated by its interaction with the MDMX protein. J Cell Biochem 2003, 88:557-568.
• [16]Kadakia M, Brown TL, McGorry MM, Berberich SJ: MdmX inhibits Smad transactivation. Oncogene 2002, 21:8776-8785.
• [17]Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M: MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999, 447:5-9.
• [18]Badciong JC, Haas AL: MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem 2002, 277:49668-49675.
• [19]Maehama T, Fukasawa M, Date T, Wakita T, Hanada K: A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. Biochem Biophys Res Commun 2013, 440:150-156.
• [20]Lafitte M, Moranvillier I, Garcia S, Peuchant E, Iovanna J, Rousseau B, Dubus P, Guyonnet-Duperat V, Belleannee G, Ramos J, Bedel A, de Verneuil H, Moreau-Gaudry F, Dabernat S: FGFR3 has tumor suppressor properties in cells with epithelial phenotype. Mol Cancer 2013, 12:83. BioMed Central Full Text
• [21]Croquelois A, Blindenbacher A, Terracciano L, Wang X, Langer I, Radtke F, Heim MH: Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005, 41:487-496.
• [22]Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS: GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN.Oncogene 2013. doi:10.1038/onc.2013.1437.
• [23]Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS: Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008, 29:541-551.
• [24]Huang KT, Huang YH, Li P, He B, Chen ZK, Yu X, Chen JO, Zhang QY, Shi HQ, Shan YF: The correlation between TSC2 and GSK3beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy.Hepatol Res 2013. doi:10.1111/hepr.12256.
• [25]Deshpande R, Asiedu MK, Klebig M, Sutor S, Kuzmin E, Nelson J, Piotrowski J, Shin SH, Yoshida M, Costanzo M, Boone C, Wigle DA, Myers CL: A comparative genomic approach for identifying synthetic lethal interactions in human cancer. Cancer Res 2013, 73:6128-6136.
• [26]Folpe AL, Deyrup AT: Alveolar soft-part sarcoma: a review and update. J Clin Pathol 2006, 59:1127-1132.
• [27]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [28]Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clement B: Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012, 72:2533-2542.
• [29]Lee JH, Lee GT, Woo SH, Ha YS, Kwon SJ, Kim WJ, Kim IY: BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res 2013, 73:3604-3614.
• [30]Kallioniemi A: Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior. Cancer Genet 2012, 205:267-277.
• [31]Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129.
• [32]Yeh SH, Chen PJ: Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010, 78(Suppl 1):172-179.
• [33]Kojiro M: Chapter 4, Morphologic evolution of hepatocellular carcinoma: from early to advanced. Pathology of Hepatocellular Carcinoma Kojiro 2006, 51-62.
• [34]AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY; 2010.
• [35]van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, Nederlof PM: A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer 2006, 94:333-337.
• [36]Diskin SJ, Eck T, Greshock J, Mosse YP, Naylor T, Stoeckert CJ Jr, Weber BL, Maris JM, Grant GR: STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res 2006, 16:1149-1158.
• [37]Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
• [38]Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
• [39]Swofford D: PAUP: Phylogenetic Analysis Using Parsimony. Version 3.1.1. National Museum of Natural History, Washington, DC; 1993.
• [40]Liu YJ, Hall BD: Body plan evolution of ascomycetes, as inferred from an RNA polymerase II phylogeny. Proc Natl Acad Sci U S A 2004, 101:4507-4512.